Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.47 |
| ▸ | GLUL | P15104 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8467545 | 1.00 | OTC (0.47) | OTCGLULGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1431004 | 1.00 | OTC (0.47) | OTCGLULGRIN2DGRIN3BGRIN1 | |
| SCHEMBL25323809 | 0.79 | GRM8 (0.54) | OTCGLULGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4255161 | 0.79 | GRM8 (0.54) | OTCGLULGRIN2DGRIN3BGRIN1 | |
| SCHEMBL9003848 | 0.79 | SLC7A5 (0.39) | GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL9003840 | 0.79 | SLC7A5 (0.39) | GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL9003756 | 0.76 | OTC (0.58) | OTCGLULGRIN2DGRIN3BGRIN1 | |
| SCHEMBL20640411 | 0.76 | CYP2D6 (0.39) | OTCGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9003744 | 0.76 | OTC (0.58) | OTCGLULGRIN2DGRIN3BGRIN1 | |
| SCHEMBL9003696 | 0.76 | CYP2D6 (0.39) | OTCGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3168563-B2 | — | — | 2001-05-21 | — | — | JP | claimed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0613459-B1 | N-TRITYL ASPARTIC ACID DERIVATIVES FOR PREPARING PHOSPHONATE NMDA ANTAGONISTS | MERRELL DOW PHARMA (US) | 1996-03-06 | — | — | EP | claimed |
| EP-0418863-B1 | NMDA antagonists | MERRELL DOW PHARMA (US) | 1995-01-04 | — | — | EP | claimed |
| EP-0613459-A1 | N-TRITYL ASPARTIC ACID DERIVATIVES FOR PREPARING PHOSPHONATE NMDA ANTAGONISTS. | MERRELL DOW PHARMA (US) | 1994-09-07 | — | — | EP | claimed |
| WO-1993010075-A1 | N-TRITYL ASPARTIC ACID DERIVATIVES FOR PREPARING PHOSPHONATE NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | claimed |
| US-20220054435-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | STUART L. WEG | 2022-02-24 | — | — | US | disclosed |
| US-20170204127-A1 | COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS | SYNTHONICS INC (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9624256-B2 | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients | SYNTHONICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20160175266-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-0613459-A1 | N-TRITYL ASPARTIC ACID DERIVATIVES FOR PREPARING PHOSPHONATE NMDA ANTAGONISTS. | MERRELL DOW PHARMA (US) | 1994-09-07 | — | — | EP | disclosed |
| WO-1994017795-A1 | USE OF INHIBITORS OF ORNITHINE AMINOTRANSFERASE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994001094-A1 | DRUGS FOR PREVENTING THE DEVELOPMENT OF TOLERANCE DURING TREATMENT WITH BENZODIAZEPINE-RECEPTOR-BINDING SUBSTANCES | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-20 | — | — | WO | disclosed |
| WO-1993010075-A1 | N-TRITYL ASPARTIC ACID DERIVATIVES FOR PREPARING PHOSPHONATE NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-05-27 | — | — | WO | disclosed |
| EP-0527540-A1 | Medicament for the treatment of withdrawal symptoms | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-02-17 | — | — | EP | disclosed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | disclosed |
| CN-1050387-A | The N-methyl-D-aspartate antagonist | MERRELL DOW PHARMA (US) | 1991-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175266-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | OTC 1451/4885GLUL 1309/4885GRIN2D 9/4885 |
| US-20170204127-A1 | COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS | PDE8A, MC2R, PKD1 | OTC 110/4885GLUL 3512/4885GRIN2D 3950/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | OTC 91/4885GLUL 2850/4885GRIN2D 1313/4885 |
| US-20220054435-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | OTC 1451/4885GLUL 1309/4885GRIN2D 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.